TC
REGN icon

Telemus Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Telemus Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$703K Buy
800
+1
+0.1% +$823 0.06% 196
2023
Q3 		$658K Sell
799
-3
-0.4% -$2.36K 0.06% 192
2023
Q2 		$576K Buy
802
+221
+38% +$170K 0.05% 209
2023
Q1 		$477K Sell
581
-21
-3% -$15.8K 0.04% 221
2022
Q4 		$444K Buy
602
+29
+5% +$21.4K 0.04% 234
2022
Q3 		$395K Hold
573
– – 0.04% 224
2022
Q2 		$339K Buy
573
+202
+54% +$131K 0.03% 269
2022
Q1 		$259K Buy
371
+6
+2% +$3.8K 0.02% 298
2021
Q4 		$231K Sell
365
-2
-0.5% -$1.23K 0.02% 341
2021
Q3 		$222K Sell
367
-1,213
-77% -$753K 0.02% 319
2021
Q2 		$882K Buy
1,580
+150
+10% +$76K 0.06% 184
2021
Q1 		$693K Buy
1,430
+570
+66% +$278K 0.05% 241
2020
Q4 		$415K Sell
860
-707
-45% -$382K 0.03% 279
2020
Q3 		$940K Buy
1,567
+995
+174% +$603K 0.07% 202
2020
Q2 		$355K Hold
572
– – 0.03% 319
2020
Q1 		$351K Buy
+572
New +$236K 0.03% 293
2018
Q1 		– Sell
-40
Closed -$15K – 520
2017
Q4 		$15K Sell
40
-4,004
-99% -$1.62M ﹤0.01% 487
2017
Q3 		$1.81M Hold
4,044
– – 0.21% 88
2017
Q2 		$1.99M Buy
+4,044
New +$1.77M 0.2% 85

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Telemus Capital's REGN Position: Q4 2023 in Review

Telemus Capital increased its Regeneron Pharmaceuticals (REGN) stake by 0.13% in Q4 2023, buying an estimated $823 and bringing the position to 800 shares worth $703K. The position accounts for 0.06% of the portfolio, ranked #196.

Telemus Capital first reported a position in REGN in Q2 2017 and has held it in 19 quarters since. The position peaked at $1.99M in Q2 2017. 1,273 funds tracked by Wall St. Rank hold REGN as of Q4 2023.

  • Telemus Capital held 800 shares of Regeneron Pharmaceuticals worth $703K as of Q4 2023.
  • Telemus Capital bought 1 Regeneron Pharmaceuticals share in Q4 2023, an estimated $823.
  • Regeneron Pharmaceuticals made up 0.06% of Telemus Capital's portfolio in Q4 2023, its #196 holding.
  • Telemus Capital first reported a position in Regeneron Pharmaceuticals in Q2 2017 and has held it in 19 quarters since.
  • Telemus Capital's Regeneron Pharmaceuticals position peaked at $1.99M in Q2 2017.
  • 1,273 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2023.

Based on Telemus Capital's 13F filing for Q4 2023, filed 1 Feb 2024.